TITLE

II. PENDING MERGERS AND ACQUISITIONS

PUB. DATE
December 2013
SOURCE
BioWorld Insight;12/2/2013, Vol. 21 Issue 49, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
A table is presented which lists global biotech companies' pending mergers and acquisition as of December 2013 including Imugene Ltd., Perrigo Co. and Theraclone Sciences Inc.
ACCESSION #
93924039

 

Related Articles

  • Financings Roundup. Shaffer, Catherine // BioWorld Today;3/27/2013, Vol. 24 Issue 58, p4 

    The article reports that Theraclone Sciences Inc. of Seattle received 14 million U.S. dollars in financing.

  • Financings Roundup.  // BioWorld Today;9/12/2011, Vol. 22 Issue 176, p4 

    The article reports on the additional 10.6 million U.S. dollars gained by Theraclone Sciences Inc. as part of its Series B financing which will be used to fund its clinical trials.

  • IMUGENE RECEPTOR MIMIC TECHNOLOGY PATENT GRANTED IN U.S.  // Worldwide Biotech;Mar2005, Vol. 17 Issue 3, p1 

    Reports on a patent granted by the U.S. to Imugene for its Receptor Mimic Technology through 2020. Importance of the technology to prevent the development of diarrhea in pigs; Ability of the receptor mimic product to bind toxins and bacteria which cause gastrointestinal diseases to mammals;...

  • Theraclone, Pfizer Ink Antibody Agreement Worth up to $632M. Powers, Marie // BioWorld Today;1/20/2011, Vol. 22 Issue 13, p1 

    The article reports on the decision of Theraclone Sciences Inc. to sign a 632-million U.S. dollar multi-year research and development cooperation with Pfizer Inc., for the in situ therapeutic antibody rescue (I-STAR) technology. The agreement involves the use of the I-STAR technology in the...

  • ICAAC Roundup.  // BioWorld Today;9/11/2012, Vol. 23 Issue 176, p7 

    This section offers news briefs on data presented at the 2012 Interscience Conference on Antimicrobial Agents and Chemotherapy meeting in San Francisco, California. Durata Therapeutics Inc. released data from a study of the effectiveness of dalbavancin. NanoBio Corp. announced data about its...

  • Clinic Roundup.  // BioWorld Today;4/3/2013, Vol. 24 Issue 63, p9 

    This section presents updates related to the biotechnology industry. The U.S. Food and Drug Administration (FDA) accepted the investigational new drug application of Ampio Pharmaceuticals Inc. FDA issued a notice of allowance to Cleveland BioLabs Inc. and Incuron LLC for an investigational new...

  • Companies Using Different Tactics to Fight Mutating Flu. Orelli, Brian // BioWorld Insight;10/21/2013, Vol. 21 Issue 43, p3 

    In this article the author discuses different drugs to fight with mutating flue. It sates that Nanoviricides Inc has developed nanoparticle technology which mimics the surface of a cell; it also mentions Theraclone Sciences Inc. which has developed the conserved region of the virus. It also...

  • Theraclone Sciences Announces Initiation of a Phase 1 Clinical Trial of TCN-202, an Antibody in Development for the Treatment of Human Cytomegalovirus Infection.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article provides information on first dosing of subjects in a Phase 1 clinical trial of TCN-202, a human monoclonal antibody by Theraclone Sciences Inc. for the treatment of human cytomegalovirus (CMV) infection. It informs that CMV transmission during pregnancy can cause permanent...

  • Clinic Roundup.  // BioWorld Today;10/26/2012, Vol. 23 Issue 209, p8 

    This section offers news briefs on clinical trials. Target enrollment has been reached by Durata Therapeutics for its second Phase III trial of dalbavancin. Positive results were obtained by QLT Inc. from two Phase II studies of the latanoprost punctal plug delivery system in patients with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics